New business development and pathology leaders strengthen GTC’s scientific depth, clinical expertise and ability to serve clinicians, laboratories and strategic partners. LAKE FOREST, Calif. —
GTC will spotlight DNA and RNA-based precision oncology testing, liquid biopsy applications and research across hematologic malignancies, breast cancer metastasis and CNS involvement CHICAGO, May
GTC presented abstracts at the 2025 Annual Meeting of the Society for Neuro-Oncology (SNO). GTC participated in the 30th Annual Meeting & Education Day of
GTC posters at 67th ASH® Annual Meeting (2025) We are delighted to share that GTC collaborated on 12 abstracts at the ASH 2025 Annual Meeting
GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please
The research addresses the challenge of disease relapse, a primary cause of treatment failure post-hematopoietic stem cell transplantation. By employing next-generation sequencing of cfDNA to monitor donor cell chimerism and minimal residual disease (MRD) early after transplantation, the study identifies patients at increased risk of relapse. This approach allows for potential early intervention with consolidation therapy, aiming to mitigate the risk of treatment failure.
GTC presented abstracts at ASH 2024 GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out
New Paper in Journal of Clinical Pathways GTC has participated in a new paper titled: Bringing Value to Health Care. Read the paper as it
GTC presented abstracts at ASCO 2024 GTC’s posters from 2024 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach
GTC presented abstracts at ASH 2023 GTC’s posters from 2023 Convention of American Society of Hematology are now available to be downloaded. Please reach out
